Uncovering the biology of multiple myeloma among African Americans: A comprehensive genomics approach

Blood

Volumn 121, Issue 16, 2013, Pages 3147-3152

  Baker, Angela ^a   Braggio, Esteban ^b   Jacobus, Susanna ^c   Jung, Sungwon ^a   Larson, Dirk ^d   Therneau, Terry ^d   Dispenzieri, Angela ^d   Van Wier, Scott A ^b   Ahmann, Gregory ^b   Levy, Joan ^e   Perkins, Louise ^e   Kim, Seungchan ^a   Henderson, Kimberly ^d   Vesole, David ^f   Vincent Rajkumar, S ^d   Jelinek, Diane F ^d   Carpten, John ^a   Fonseca, Rafael ^b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

^e Myeloma Research Consortium   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN HEAVY CHAIN; RNA;

AFRICAN AMERICAN; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOGENETICS; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; HUMAN GENOME; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; GENE TRANSLOCATION; GENETICS; GENOMICS; METHODOLOGY;

AFRICAN AMERICANS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC;

MLCS; MLOWN;

EID: 84879144365     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-443606     Document Type: Article

References (42)

1. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22):5418-5422.
2. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood. 2009;113(22):5412-5417.
3. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3): 904-906.
4. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12): 1468-1473.
5. Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116(7):1056-1059.
6. StatBite. StatBite: Multiple myeloma and African Americans: Higher incidence but fewer autologous stem cell transplants. J Natl Cancer Inst. 2009; 101(23):1610.
7. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: Support for genetic factors in pathogenesis. Leukemia. 2009;23(10):1691-1697.
8. Weiss BM, Minter A, Abadie J, et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. Am J Hematol. 2011;86(6):475-478.
9. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: A population-based study. Blood. 2010; 116(25):5501-5506.
10. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C; Groupe Français de Cytogénétique Hématologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229-2238.
11. Chng WJ, Santana-Dávila R, Van Wier SA, et al. Prognostic factors for hyperdiploidmyeloma: Effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20(5): 807-813.
12. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3-12.
13. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106(6):2156-2161.
14. Decaux O, Lodé L, Magrangeas F, et al; Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26(29): 4798-4805.
15. Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-2553.
16. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
17. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339): 467-472.
18. Oken MM, Leong T, Lenhard RE Jr, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: Phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999;86(6): 957-968.
19. Fonseca R, Oken MM, Greipp PR; Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood. 2001;98(4): 1271-1272.
20. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735-3741.
21. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11): 4569-4575.
22. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An eastern cooperative oncology group study. Cancer Res. 2002;62(3):715-720.
23. Rajkumar SV, Jacobus S, Callander NS, et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol. 2010; 11(1):29-37.
24. Wu KL, Beverloo B, Lokhorst HM, et al; Dutch- Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC). Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007; 136(4):615-623.
25. Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15): E56-e65.
26. Leone PE, Walker BA, Jenner MW, et al. Deletions of CDKN2C in multiple myeloma: Biological and clinical implications. Clin Cancer Res. 2008;14(19):6033-6041.
27. Gutiérrez NC, García JL, Hernández JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104(9):2661-2666.
28. Avet-Loiseau H, Facon T, Grosbois B, et al; Intergroupe Francophone du Myélome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185-2191.
29. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27(27):4585-4590.
30. Jenner MW, Leone PE, Walker BA, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9): 3291-3300.
31. Agresti A. A survey of exact interference for contingency tables. Stat Sci. 1992;7(1):131-153.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.
33. Brousseau M, Leleu X, Gerard J, et al; Intergroupe Francophone du Myélome. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res. 2007;13(20): 6026-6031.
34. Agnelli L, Fabris S, Bicciato S, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 2007;136(4):565-573.
35. Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. Am J Hematol. 2007;82(12): 1080-1087.
36. Greslikova H, Zaoralova R, Filkova H, et al. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Neoplasma. 2010;57(2):111-117.
37. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495.
38. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26): 6333-6338.
39. Kuehl WM, Bergsagel PL. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187.
40. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2):131-144.
41. Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2010;148(5):702-713.
42. Tiedemann RE, Zhu YX, Schmidt J, et al. Kinomewide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010; 115(8):1594-1604.